Terminated PHASE1 INTERVENTIONAL 2-arm NCT04322227

Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects

Interventional, Randomized, Double-blind, Placebo-controlled Three-way Crossover Study Investigating the Pharmacodynamic Effects of Two Doses of Foliglurax Using Electroencephalography in Patients With Parkinson's Disease and in Healthy Subjects

Sponsor: H. Lundbeck A/S

Conditions Healthy Parkinson Disease

Interventions Foliglurax 10 mg (treatment A) Foliglurax 30 mg (treatment B) Placebo (treatment C)

Updated 5 times since 2020 Last updated: Jul 3, 2020 Started: Jan 23, 2020 Primary completion: May 30, 2020 Completion: May 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study termination due to efficacy results of another study

Other terminated trials from H. Lundbeck A/S

See all terminations from H. Lundbeck A/S

Other Healthy trials with similar outcome

Browse all Healthy trials

A PHASE1 clinical study on Healthy and Parkinson Disease, this trial is terminated or withdrawn. The trial is conducted by H. Lundbeck A/S and has accumulated 5 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Aug 2020 — Jan 2021 [monthly]

Terminated PHASE1

Status: Recruiting → Terminated
Apr 2020 — Aug 2020 [monthly]

Recruiting PHASE1

First recorded

Jan 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

H. Lundbeck A/S

Data source: H. Lundbeck A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rennes, France